Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022

References

• Beukelman T, Xie F, Foeldvari I. Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States. J Scleroderma Relat Disord. 2018;3(2):189–190. doi: 10.1177/2397198318763701
   PubMedGoogle Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327–1339. doi: 10.1136/annrheumdis-2016-209909
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009 May;68(5):620–8.
   PubMed Web of Science ®Google Scholar
• Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016 Oct;55(10):1906–10. doi: 10.1093/rheumatology/kew224
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Klotsche J, Kasapcopur O, et al. Differences sustained between diffuse and limited forms of juvenile systemic sclerosis in an expanded international cohort. Arthritis Care Res (Hoboken). 2022 Oct;74(10):1575–1584. doi: 10.1002/acr.24609
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology (Oxford). 2021 Apr 6;60(4):1651–1658. doi: 10.1093/rheumatology/keaa584
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Torok KS, Klotsche J, et al. Proposed response parameters for twelve-month drug trial in juvenile systemic sclerosis: results of the Hamburg International Consensus Meetings. Arthritis Care Res (Hoboken). 2023 Jun 18;75(12):2453–2462. doi: 10.1002/acr.25171
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Klotsche J, Kasapcopur O, et al. Juvenile Systemic Sclerosis treatment practices in an international cohort and comparison to recent SHARE consensus guidelines. Arthritis & Rheumat. 2022;74(Suppl 9). Abstract 0515.
   Google Scholar
• Stevens BE, Torok KS, Li SC, et al. Clinical characteristics and factors associated with disability and impaired quality of life in children with juvenile systemic sclerosis: results from the childhood Arthritis and Rheumatology Research Alliance legacy registry. Arthritis Care Res (Hoboken). 2018 Dec;70(12):1806–1813. doi: 10.1002/acr.23547
   PubMed Web of Science ®Google Scholar
• Liem SIE, van Leeuwen NM, Vliet Vlieland TPM, et al. Physical therapy in systemic sclerosis: the patient perspective. Arthritis Care Res (Hoboken). 2023 Jan;75(1):145–151. doi: 10.1002/acr.24741
   PubMed Web of Science ®Google Scholar
• Murphy SL, Berrocal V, Poole J, et al. Reliability, validity, and responsiveness to change of the patient-reported outcomes measurement information system selfefficacy for managing chronic conditions measure in systemic sclerosis. J Scleroderma Relat Disord. 2021;7(2):1–7. doi: 10.1177/23971983211049846
   Web of Science ®Google Scholar
• Murphy SL, Poole JL, Chen YT, et al. Rehabilitation interventions in systemic sclerosis: a systematic review and future directions. Arthritis Care Res (Hoboken). 2022 Jan;74(1):59–69. doi: 10.1002/acr.24737
   PubMed Web of Science ®Google Scholar
• van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996 Apr;35(4):364–372.
   PubMedGoogle Scholar
• Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001 Jun;44(6):1351–8.
   PubMed Web of Science ®Google Scholar
• Martini G, Saggioro L, Culpo R, et al. Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma. Rheumatology (Oxford). 2021 Sep 25;60(3):1387–1391. doi: 10.1093/rheumatology/keaa392
   PubMed Web of Science ®Google Scholar
• Fernandez-Codina A, Walker KM, Pope JE, et al. Treatment algorithms for systemic sclerosis according to experts. Arthritis & rheumat. 2018 Nov;70(11):1820–1828.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708–719.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018 Jun;77(6):819–828.
   PubMed Web of Science ®Google Scholar
• Khanna D, Lescoat A, Roofeh D, et al. Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice. Arthritis & rheumat. 2022 Jan;74(1):13–27. doi: 10.1002/art.41933
   PubMed Web of Science ®Google Scholar
• Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014 Jan;73(1):3–5.
   PubMed Web of Science ®Google Scholar
• Khanna D, Furst D, Goldin J, et al. Tocilizumab in systemic sclerosis: a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–974. publishehd August 28, 2020. doi: 10.1016/S2213-2600(20)30318-0
   PubMed Web of Science ®Google Scholar
• Hughes M, Denton CP, Khanna D. Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology (Oxford). 2021 Feb 1;60(2):489–491. doi: 10.1093/rheumatology/keaa675
   PubMed Web of Science ®Google Scholar
• Khanna D, Padilla C, Tsoi LC, et al. Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial. JCI Insight. 2022 Sep 8;7(17). doi: 10.1172/jci.insight.159566
   Web of Science ®Google Scholar
• Karalilova RV, Batalov ZA, Sapundzhieva TL, et al. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int. 2021 Oct;41(10):1743–1753.
   PubMed Web of Science ®Google Scholar
• Mulcaire-Jones E, Low AHL, Domsic R, et al. Advances in biological and targeted therapies for systemic sclerosis. Expert Opin Biol Ther. 2023 Apr;23(4):325–339.
   PubMedGoogle Scholar
• van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014 Jun 25;311(24):2490–2498. doi: 10.1001/jama.2014.6368
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018 Jan 4;378(1):35–47. doi: 10.1056/NEJMoa1703327
   PubMed Web of Science ®Google Scholar
• Torok K, Horvei P, Rosser F, et al. Improvement in clinical and patient-reported outcomes for refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 months to 2 years after autologous stem cell transplantation (ASCT) [Abstract]. Arthritis Rheumatol. 2023;75(Suppl 9):L06.
   Google Scholar
• Torok K, Rosser F, Rose-Felker K, et al. Transcriptomic evaluation of juvenile localized scleroderma skin with histologic and clinical correlation. Arthritis Rheumatol. 2021;73(10):1921–1930. doi: 10.1002/art.41758
   PubMed Web of Science ®Google Scholar
• Martini A, Maccario R, Ravelli A, et al. Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. Rheumatol. 1999 Aug;38(8):773.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Perotti C, Torretta L, et al. Mobilization and selection of peripheral blood hematopoietic progenitors in children with systemic sclerosis. Haematologica. 1999;84:839–843.
   PubMed Web of Science ®Google Scholar
• Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis. 2004 Aug;63(8):974–981.
   PubMed Web of Science ®Google Scholar
• Rimar D, Butbul Aviel Y, Gefen A, et al. Autologous Hematological Stem Cell Transplantation for Systemic Sclerosis in Israel. Isr Med Assoc J. 2020 Feb;22(2):104–110.
   PubMed Web of Science ®Google Scholar
• Shah A, Spierings J, van Laar JM, et al. Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature. J Scleroderma Relat Disord. 2021 Jun;6(2):199–205.
   PubMed Web of Science ®Google Scholar
• Park R, Nevskaya T, Baron M, et al. Immunosuppression use in early systemic sclerosis may be increasing over time. J Scleroderma Relat Disord. 2022 Feb;7(1):33–41.
   PubMed Web of Science ®Google Scholar
• Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind,investigaor-initated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):e489–97. doi: 10.1016/S2665-9913(21)00107-7
   PubMedGoogle Scholar
• Elhai M, Boubaya M, Distler O, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019 Apr 9;78(7):979–987. doi: 10.1136/annrheumdis-2018-214816
   PubMed Web of Science ®Google Scholar
• Zulian F, Dal Pozzolo R, Meneghel A, et al. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatol. 2020 Dec 1;59(12):3793–3797. doi: 10.1093/rheumatology/keaa193
   PubMed Web of Science ®Google Scholar
• Castellvi I, Elhai M, Bruni C, et al. Safety and effectiveness of abatacept in systemic sclerosis: the EUSTAR experience. Semin Arthritis Rheum. 2020 Dec;50(6):1489–1493. doi: 10.1016/j.semarthrit.2019.12.004
   PubMed Web of Science ®Google Scholar
• Khanna D, Spino C, Johnson S, et al. Abatacept in early diffuse cutaneous systemic sclerosis - results of a phase 2 investigator-initiated, multicenter, double-blind randomized placebo-controlled trial. Arthritis & Rheumat. 2000 [cited 2019 Jul 24];72:125–136.
   Google Scholar
• Fernandez-Lazaro D, Iglesias-Lazaro M, Garrosa E, et al. Impact of innovative treatment using biological drugs for the modulation of diffuse cutaneous systemic sclerosis: a systematic review. Medicina (Kaunas). 2023 Jan 27;59(2):247. doi: 10.3390/medicina59020247
   PubMed Web of Science ®Google Scholar
• Mitropoulos A, Gumber A, Crank H, et al. Exploring the feasibility of an exercise programme including aerobic and resistance training in people with limited cutaneous systemic sclerosis. Clin Rheumatol. 2020 Jan 14;39(6):1889–1898. doi: 10.1007/s10067-019-04921-7
   PubMed Web of Science ®Google Scholar
• Murphy SL, Barber MW, Homer K, et al. Occupational therapy treatment to improve upper extremity function in individuals with early systemic sclerosis: a pilot study. Arthritis Care Res (Hoboken). 2018 Nov;70(11):1653–1660.
   PubMed Web of Science ®Google Scholar
• Gregory WJ, Wilkinson J, Herrick AL. A randomised controlled trial of wax baths as an additive therapy to hand exercises in patients with systemic sclerosis. Physiotherapy. 2019 Sep;105(3):370–377. doi: 10.1016/j.physio.2018.08.008
   PubMed Web of Science ®Google Scholar
• Knobler R, Moinzadeh P, Hunzelmann N, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1401–1424.
   PubMed Web of Science ®Google Scholar
• Kroft EB, Groeneveld TJ, Seyger MM, et al. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol. 2009;10(3):181–187. doi: 10.2165/00128071-200910030-00004
   PubMed Web of Science ®Google Scholar
• Pope E, Doria AS, Theriault M, et al. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study. Dermatology. 2011;223(4):363–9. doi: 10.1159/000335560
   PubMed Web of Science ®Google Scholar
• Dytoc M, Wat H, Cheung-Lee M, et al. Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial. J Cutan Med Surg. 2015 Mar;19(2):132–9.
   PubMed Web of Science ®Google Scholar
• Cunningham BB, Landells ID, Langman C, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998 Aug;39(2 Pt 1):211–215.
   PubMed Web of Science ®Google Scholar
• Kreuter A, Breuckmann F, Uhle A, et al. Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol. 2004 May;50(5):740–7.
   PubMed Web of Science ®Google Scholar
• Connolly KL, Griffith JL, McEvoy M, et al. Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients. Photodermatol Photoimmunol Photomed. 2015 Nov;31(6):289–295.
   PubMed Web of Science ®Google Scholar
• Thompson KG, Kim N. Distinguishing Myth from Fact: Photocarcinogenesis and Phototherapy. Dermatol Clin. 2020 Jan;38(1):25–35. doi: 10.1016/j.det.2019.08.003
   PubMed Web of Science ®Google Scholar
• Goulden V, Ling TC, Babakinejad P, et al. British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022. Br J Dermatol. 2022 Sep;187(3):295–308.
   PubMed Web of Science ®Google Scholar
• Weibel L. Localized scleroderma (morphea) in childhood. Hautarzt. 2012 Feb;63(2):89–96. doi: 10.1007/s00105-011-2199-5
   PubMed Web of Science ®Google Scholar
• Dinsdale G, Murray A, Moore T, et al. A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology (Oxford). 2014 Aug;53(8):1422–30.
   PubMed Web of Science ®Google Scholar
• Morrisroe KB, Nikpour M, Proudman SM. Musculoskeletal Manifestations of Systemic Sclerosis. Rheum Dis Clin North Am. 2015 Aug;41(3):507–18. doi: 10.1016/j.rdc.2015.04.011
   PubMed Web of Science ®Google Scholar
• Li S, McCormick Q. Paediatric Scleroderma: Kids Are Not Just Little Adults. EMJ Rheumatol. 2022;9:47–58. doi: 10.33590/emjrheumatol/22-00107
   Google Scholar
• Sandler R, Matucci Cerinic M, Hughes M. Musculoskeletal hand invovlement in systemic sclerosis. Semin Arthritis Rheum. 2020;50(2):329–334. doi: 10.1016/j.semarthrit.2019.11.003
   PubMed Web of Science ®Google Scholar
• Arslan D, Turk I, Kozanoglu E, et al. Sacroiliitis detected by magnetic resonance imaging in patients with systemic sclerosis. Arch Rheumatol. 2020 Dec;35(4):515–520.
   PubMed Web of Science ®Google Scholar
• Fairchild R, Horomanski A, Sharpless L, et al. Ultrasound evaluation of the hands and wrists in patients with systemic sclerosis: osteophytosis is a major contributor to tender joints. Semin Arthritis Rheum. 2021;51(4):733–740. doi: 10.1016/j.semarthrit.2021.04.020
   Web of Science ®Google Scholar
• Dibrov D, Starovoytova M, Desinova O. AB0855 Fibrous arthropathy as the key feature of juvenile scleroderma - case report. Ann Rheum Dis. 2021;80(Suppl 1):1451.2–1451. doi: 10.1136/annrheumdis-2021-eular.2840
   Google Scholar
• Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017 Jul;76(7):1207–1218.
   PubMed Web of Science ®Google Scholar
• Zacay G, Levy Y. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. Best Pract Res Clin Rheumatol. 2018 Aug;32(4):563–571. doi: 10.1016/j.berh.2019.01.011
   PubMed Web of Science ®Google Scholar
• Panopoulos ST, Tektonidou MG, Bournia VK, et al. Anti-interleukin 6 therapy effect for refractory joint and skin involvement in systemic sclerosis: a real-world, single-center experience. J Rheumatol. 2022 Jan;49(1):68–73.
   PubMed Web of Science ®Google Scholar
• Funauchi M, Kinoshita K. Problems to consider before determining the regimen of the treatment for juvenile systemic sclerosis treatment: a case report where tocilizumab monotherapy succeeded efficiently and safely. Clin Med Insights Arthritis Musculoskelet Disord. 2022;15:11795441211066307. doi: 10.1177/11795441211066307
   Web of Science ®Google Scholar
• Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013 Jul;72(7):1217–20. doi: 10.1136/annrheumdis-2012-202657
   PubMed Web of Science ®Google Scholar
• Omair MA, Phumethum V, Johnson SR. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol. 2012 Mar;30(2 Suppl 71):S55–9.
   PubMed Web of Science ®Google Scholar
• Giuggioli D, Lumetti F, Colaci M, et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015 Nov;14(11):1072–8.
   PubMed Web of Science ®Google Scholar
• Yarkan Tugsal H, Zengin B, Kenar G, et al. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature. Int J Rheum Dis. 2022 Jul;25(7):755–768.
   PubMed Web of Science ®Google Scholar
• Moriana C, Moulinet T, Jaussaud R, et al. JAK inhibitors and systemic sclerosis: a systematic review of the literature. Autoimmun Rev. 2022 Oct;21(10):103168. doi: 10.1016/j.autrev.2022.103168
   PubMed Web of Science ®Google Scholar
• Agostini E, De Luca G, Bruni C, et al. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from systematic literature review and from real life experience. Autoimmun Rev. 2021 Dec;20(12):102981. doi: 10.1016/j.autrev.2021.102981
   PubMed Web of Science ®Google Scholar
• Bellutti Enders F, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017 Feb;76(2):329–340.
   PubMed Web of Science ®Google Scholar
• Hachulla E, Agard C, Allanore Y, et al. French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis. 2021 Jul 26;16(Suppl 2):322. doi: 10.1186/s13023-021-01844-y
   PubMed Web of Science ®Google Scholar
• Lopez-Ovejero JA, Saal SD, D’Angelo WA, et al. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med. 1979 Jun 21;300(25):1417–9. doi: 10.1056/NEJM197906213002505
   PubMed Web of Science ®Google Scholar
• Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990 Sep 1;113(5):352–357. doi: 10.7326/0003-4819-113-5-352
   PubMed Web of Science ®Google Scholar
• Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis. 2008 Jan;67(1):110–6.
   PubMed Web of Science ®Google Scholar
• Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017 Sep;140(3): doi: 10.1542/peds.2017-1904
   PubMed Web of Science ®Google Scholar
• Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK scleroderma study group: digital vasculopathy in systemic sclerosis. Rheumatol. 2015 Nov;54(11):2015–24. doi: 10.1093/rheumatology/kev201
   PubMed Web of Science ®Google Scholar
• Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatol. 2004 Feb;43(2):229–233.
   PubMed Web of Science ®Google Scholar
• Gargh K, Baildam EM, Cleary GA, et al. A retrospective clinical analysis of pharmacological modalities used for symptomatic relief of Raynaud’s phenomenon in children treated in a UK paediatric rheumatology centre. Rheumatol. 2010 Jan;49(1):193–4.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Hashida Y, Ueno K, et al. Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis. Pediatr Cardiol. 2011 Oct;32(7):1040–2.
   PubMed Web of Science ®Google Scholar
• Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001 Aug;44(8):1841–7.
   PubMed Web of Science ®Google Scholar
• Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013 Oct;72(10):1696–9.
   PubMed Web of Science ®Google Scholar
• Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;1998(2):CD000953. 10.1002/14651858.CD000953
   PubMedGoogle Scholar
• Giuggioli D, Manfredi A, Lumetti F, et al. Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature. Autoimmun Rev. 2018 Feb;17(2):155–164.
   PubMed Web of Science ®Google Scholar
• Hughes M, Alcacer-Pitarch B, Allanore Y, et al. Digital ulcers: should debridement be a standard of care in systemic sclerosis? Lancet Rheumatol. 2020;2(5):e302–e307. doi: 10.1016/S2665-9913(19)30164-X
   PubMedGoogle Scholar
• Lebedoff N, Frech TM, Shanmugam VK, et al. Review of local wound management for scleroderma-associated digital ulcers. J Scleroderma Relat Disord. 2018 Feb;3(1):66–70. doi: 10.5301/jsrd.5000268
   PubMed Web of Science ®Google Scholar
• Hughes M, Alcacer-Pitarch B, Gheorghiu AM, et al. Digital ulcer debridement in systemic sclerosis: a systematic literature review. Clin Rheumatol. 2020 Mar;39(3):805–811.
   PubMed Web of Science ®Google Scholar
• Hughes M, Moore T, Manning J, et al. Reduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrate. Microvasc Res. 2017 May;111:32–36.
   PubMed Web of Science ®Google Scholar
• Hughes M, Moore T, Manning J, et al. A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis. J DermatolTreat. 2019 May;30(3):251–257.
   Google Scholar
• Shenavandeh S, Sepaskhah M, Dehghani S, et al. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis. Clin Rheumatol. 2022 Jan;41(1):95–104.
   PubMed Web of Science ®Google Scholar
• Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992 Sep;19(9):1407–1414.
   PubMed Web of Science ®Google Scholar
• Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994 Feb 1;120(3):199–206. doi: 10.7326/0003-4819-120-3-199402010-00004
   PubMed Web of Science ®Google Scholar
• Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004 Dec;50(12):3985–93.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan;70(1):32–8.
   PubMed Web of Science ®Google Scholar
• Torok KS. Updates in systemic sclerosis treatment and applicability to pediatric scleroderma. Rheum Dis Clin North Am. 2021 Nov;47(4):757–780. doi: 10.1016/j.rdc.2021.07.004
   PubMed Web of Science ®Google Scholar
• Rahaghi FF, Hsu VM, Kaner RJ, et al. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respir Res. 2023 Jan 9;24(1):6. doi: 10.1186/s12931-022-02292-3
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Distler O, Crestani B, et al. Recent advances in the management of systemic sclerosis-associated interstitial lung disease. Curr Opin Pulm Med. 2022 Sep 1;28(5):441–447. doi: 10.1097/MCP.0000000000000901
   PubMed Web of Science ®Google Scholar
• Hoffman A, Maher TM, P E, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2020;2(2):e71–83. doi: 10.1016/S2665-9913(19)30144-4
   PubMedGoogle Scholar
• Foeldvari I, Klotsche J, Hinrichs B, et al. Underdetection of interstitial lung disease in juvenile systemic sclerosis. Arthritis Care Res (Hoboken). 2022 Mar;74(3):364–370. doi: 10.1002/acr.24499
   PubMed Web of Science ®Google Scholar
• Vonk MC, Smith V, Sfikakis PP, et al. Pharmacological treatments for SSc-ILD: systematic review and critical appraisal of the evidence. Autoimmun Rev. 2021 Dec;20(12):102978. doi: 10.1016/j.autrev.2021.102978
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655–66. doi: 10.1056/NEJMoa055120
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020 Oct;8(10):963–974. doi: 10.1016/S2213-2600(20)30318-0
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019 Jun 27;380(26):2518–2528. doi: 10.1056/NEJMoa1903076
   PubMed Web of Science ®Google Scholar
• Denton CP, Goh NS, Humphries SM, et al. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatol. 2023 May 2;62(5):1870–1876. doi: 10.1093/rheumatology/keac535
   PubMed Web of Science ®Google Scholar
• Deterding R, Young LR, DeBoer EM, et al. Nintedanib in children and adolescents with fibrosing interstitial lung diseases. Eur Respir J. 2023 Feb;61(2):2201512. doi: 10.1183/13993003.01512-2022
   PubMed Web of Science ®Google Scholar
• Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023 Jan;11(1):45–54.
   PubMed Web of Science ®Google Scholar
• Moffa A, Oliveto G, Matteo FD, et al. Modified inspiratory muscle training (m-IMT) as promising treatment for gastro-oesophageal reflux disease (GERD). Acta Otorrinolaringol Esp (Engl Ed). 2020 Mar;71(2):65–69.
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015 [2016 Jan 1];37(1):67–119. doi: 10.1093/eurheartj/ehv317
   PubMed Web of Science ®Google Scholar
• Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015 Aug 27;373(9):834–44. doi: 10.1056/NEJMoa1413687
   PubMed Web of Science ®Google Scholar
• Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and Tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102–10. doi: 10.1164/rccm.201507-1398OC
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21;132(6):425–34. doi: 10.7326/0003-4819-132-6-200003210-00002
   PubMed Web of Science ®Google Scholar
• Zamanian RT, Badesch D, Chung L, et al. Safety and efficacy of B-Cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2021 Jul 15;204(2):209–221. doi: 10.1164/rccm.202009-3481OC
   PubMed Web of Science ®Google Scholar
• Scalapino K, Arkachaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006 May;33(5):1004–13.
   PubMed Web of Science ®Google Scholar
• Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006 Dec;54(12):3971–8.
   PubMedGoogle Scholar
• Martini G, Vittadello F, Kasapcopur O, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatol. 2009 Feb;48(2):119–122.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Torok KS. Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points. Best Pract Res Clin Rheumatol. 2021 Apr 22;35(3):101688. doi: 10.1016/j.berh.2021.101688
   PubMed Web of Science ®Google Scholar
• Ambartsumyan L, Zheng HB, Iyer RS, et al. Relationship between esophageal abnormalities on fluoroscopic esophagram and pulmonary function testing in juvenile systemic sclerosis. Arthritis Care Res (Hoboken). 2019 Nov;71(11):1444–1449.
   PubMed Web of Science ®Google Scholar
• Baron M, Hudson M, Steele R, et al. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. J Rheumatol. 2011 Sep;38(9):1925–1930.
   PubMed Web of Science ®Google Scholar
• Shreiner AB, Murray C, Denton C, et al. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord. 2016;1(3):247–256. doi: 10.5301/jsrd.5000214
   PubMed Web of Science ®Google Scholar
• Suliman YA, Kafaja S, Alemam M, et al. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients. J Scleroderma Relat Disord. 2021 Oct;6(3):236–241.
   PubMed Web of Science ®Google Scholar
• Zampatti N, Garaiman A, Jordan S, et al. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis. Arthritis Res Ther. 2021 Apr 22;23(1):125. doi: 10.1186/s13075-021-02506-x
   PubMed Web of Science ®Google Scholar
• Stefancic S, Robinson A, Havrilla H, et al. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort. Arthritis Rheumatol. 2023;75.
   Web of Science ®Google Scholar
• Mills T, Price E, Walker L. Clinician and patient experiences of managing and living with oral and dental manifestations of scleroderma: A scoping review. J Scleroderma Relat Disord. 2023;I–13. doi: 10.1177/23971983231193515
   Web of Science ®Google Scholar
• Yuen HK, Weng Y, Bandyopadhyay D, et al. Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis. Clin Exp Rheumatol. 2011 Mar;29(2 Suppl 65):S26–32.
   PubMed Web of Science ®Google Scholar
• Poole J, Conte C, Brewer C, et al. Oral hygiene in scleroderma: the effectiveness of a multi-disciplinary intervention program. Disabil Rehabil. 2010;32(5):379–84. doi: 10.3109/09638280903171527
   PubMed Web of Science ®Google Scholar
• Uras C, Mastroeni S, Tabolli S, et al. A comparison between two educational methods in the rehabilitation of the microstomia in systemic sclerosis: a randomized controlled trial. Clin Rehabil. 2019 Nov;33(11):1747–1756.
   PubMed Web of Science ®Google Scholar
• Nagaraja V, McMahan ZH, Getzug T, et al. Management of gastrointestinal involvement in scleroderma. Curr Treatm Opt Rheumatol. 2015 Mar 1;1(1):82–105. doi: 10.1007/s40674-014-0005-0
   PubMedGoogle Scholar
• Pakozdi A, Wilson H, Black CM, et al. Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? Clin Exp Rheumatol. 2009 May;27(3 Suppl 54):5–8.
   PubMed Web of Science ®Google Scholar
• Cheah JX, Khanna D, McMahan Z. Management of scleroderma gastrointestinal disease: Lights and shadows. J Scleroderma Relat Disord. 2022;7(2):I–13. doi: 10.1177/23971983221086343
   Web of Science ®Google Scholar
• Chen KB, Wu ZW, Wang J, et al. Efficacy and safety of long-term transcutaneous electroacupuncture versus sham transcutaneous electroacupuncture for delayed gastric emptying after distal gastrectomy: study protocol for a randomized, patient-assessor blinded, controlled trial. Trials. 2022 Mar 3;23(1):189. doi: 10.1186/s13063-022-06108-z
   PubMed Web of Science ®Google Scholar
• Carlson DA, Hinchcliff M, Pandolfino JE. Advances in the evaluation and management of esophageal disease of systemic sclerosis. Curr Rheumatol Rep. 2015 Jan;17(1):475. doi: 10.1007/s11926-014-0475-y
   PubMed Web of Science ®Google Scholar
• Lew RJ, Kochman ML. A review of endoscopic methods of esophageal dilation. J Clin Gastroenterol. 2002 Aug;35(2):117–26. doi: 10.1097/00004836-200208000-00001
   PubMed Web of Science ®Google Scholar
• Dubecz A, Stein HJ. Endoscopic versus surgical therapy for early cancer in Barrett’s esophagus. Gastrointest Endosc. 2009 Oct;70(4):632–4. doi: 10.1016/j.gie.2009.04.020
   PubMed Web of Science ®Google Scholar
• Parodi A, Sessarego M, Greco A, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol. 2008 May;103(5):1257–62.
   PubMed Web of Science ®Google Scholar
• Garcia-Collinot G, Madrigal-Santillan EO, Martinez-Bencomo MA, et al. Effectiveness of Saccharomyces boulardii and Metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Dig Dis Sci. 2020 Apr;65(4):1134–1143.
   PubMed Web of Science ®Google Scholar
• Raja J, Nihtyanova SI, Murray CD, et al. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatol. 2016 Jan;55(1):115–9.
   PubMed Web of Science ®Google Scholar
• Smith E, Pauling JD. The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: A systematic literature review. Semin Arthritis Rheum. 2019 Aug;49(1):112–118. doi: 10.1016/j.semarthrit.2018.12.001
   PubMed Web of Science ®Google Scholar
• Vigone B, Caronni M, Severino A, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017 Jun 20;19(1):145. doi: 10.1186/s13075-017-1340-y
   PubMedGoogle Scholar
• Kenefick NJ, Vaizey CJ, Nicholls RJ, et al. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut. 2002 Dec;51(6):881–883.
   PubMed Web of Science ®Google Scholar